Ernst & Young

Magnifying glass focusing on number 2026 with target icon on yellow background

Biotech

Despite headwinds, biotech industry charges forward behind M&A

Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum, as the volume and value of M&A deals continue to increase.

Kevin Dunleavy Jun 9, 2026 12:41pm

illustration of young entrepreneur pitching idea to raise venture capital fund

Taxes, tariffs, interest rates hold key to biotech's future: EY

Jun 18, 2025 9:50am

bank vault cash open door money cash windfall

Pharma has $1T in firepower to spend on biotech innovation: EY

Jun 3, 2024 8:00am

money trend loss dollar stock down

Medtech M&A, IPOs, VC funding plummeted in 2022: EY

Oct 9, 2023 8:00am

concept of chess board with letters MA

Expect a 'buoyant year' in biopharma M&A with $1.7T to deploy

Feb 15, 2022 8:00am